exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
Published 6 years ago • 394 plays • Length 5:16Download video MP4
Download video MP3
Similar videos
-
0:44
peace-1: abiraterone plus prednisone, adt and docetaxel in mcspc
-
0:47
systemic triple therapy in metastatic hormone-sensitive prostate cancer
-
1:17
abiraterone for the treatment of cn1 prostate cancer
-
1:51
recent trials in advanced prostate cancer: stampede and adrad
-
5:59
apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mcrpc
-
3:35
real-world survival in mhspc following abiraterone or docetaxel therapy
-
1:19
highlights in prostate cancer from esmo
-
1:15
exciting times for hormone-sensitive prostate cancer treatment
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
3:38
results from peace-1: abiraterone in mcspc
-
1:19
comparing abiraterone and docetaxel in prostate cancer treatment
-
1:13
arto: local treatment in crpc undergoing abiraterone treatment
-
2:31
abiraterone: a step forward in the treatment of prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:30
bmi and clinical outcomes in patients with metastatic castration-resistant prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
5:49
adt plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: systemic review
-
2:07
chaarted2: cabazitaxel plus abiraterone vs. abiraterone alone for metastatic crpc